Anthem BioSciences ANTHEM
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Research path: Interpret Anthem BioSciences's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
AI analysis and Advanced tools for ANTHEM
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 3,429.29 | 2,807.58 | 2,398.11 |
| Accumulated Depreciation Total | -696.38 | -573.69 | -494.03 |
| Cash Equivalents | 272.91 | 171.45 | 183.86 |
| Other Liabilities Total | 32.44 | 21.6 | 18.87 |
| Accrued Expenses | 38.19 | 19.66 | 27.45 |
| Long Term Debt | 27.73 | 47.03 | 111.66 |
| Common Stock Total | 112.34 | 111.82 | 111.82 |
| Other Equity Total | -4.52 | -2.95 | -2.55 |
| Other Current Assets Total | 137.84 | 187.33 | 120.04 |
| Prepaid Expenses | 4.81 | 0.61 | 3.41 |
| Total Assets | 3,429.29 | 2,807.58 | 2,398.11 |
| Current Portof LT Debt/Capital Leases | 25.31 | 63.43 | 122.55 |
| Additional Paid-In Capital | 151.22 | 125.18 | 125.18 |
| Cash | 1.97 | 0.84 | 0.5 |
| Total Equity | 3,042.52 | 2,409.86 | 1,924.66 |
| Long Term Investments | 508.03 | 271.97 | 18.28 |
| Retained Earnings(Accumulated Deficit) | 2,783.47 | 2,175.81 | 1,690.21 |
| Total Common Shares Outstanding | 56.17 | 56.16 | 56.16 |
| Property/Plant/Equipment Total-Gross | 1,743.52 | 1,571.8 | 1,314.99 |
| Tangible Book Valueper Share Common Eq | 54.16 | 42.84 | 34.16 |
| Total Liabilities | 386.77 | 397.72 | 473.46 |
| Total Debt | 53.92 | 113.32 | 238.52 |
| Short Term Investments | 665.59 | 312.29 | 459.07 |
| Cashand Short Term Investments | 940.47 | 484.58 | 643.43 |
| Total Receivables Net | 593.5 | 459.91 | 490.64 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 |
| Accounts Receivable-Trade Net | 590.64 | 450.43 | 490.63 |
| Property/Plant/Equipment Total-Net | 1,047.14 | 998.11 | 820.97 |
| Total Current Liabilities | 325.71 | 326.23 | 338.63 |
| Total Inventory | 126.52 | 355.75 | 224.04 |
| Accounts Payable | 75.22 | 110.09 | 100.74 |
| Other Currentliabilities Total | 187 | 133.05 | 87.88 |
| Total Long Term Debt | 28.62 | 49.88 | 115.96 |
| Intangibles Net | 0.44 | 3.87 | 6.24 |
| Other Long Term Assets Total | 47.27 | 35.44 | 59.24 |
| Note Receivable-Long Term | 23.27 | 10.02 | 11.83 |
| Total Current Assets | 1,803.15 | 1,488.17 | 1,481.55 |
| Capital Lease Obligations | 0.88 | 2.86 | 4.31 |
Valuation and ratios
Valuation
PEG Ratio5.41
Price to Sale Ratio21.95
Growth
Debt 5Yr CAGR %-12.03
Margins
Operating Margin 12m31.51
Operating Margin 5y Avg34.07
Net Profit Margin 12m28.76
Net Profit Margin 5y28.67
Yield
Dividend Yield %0.24
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk27.27
Analyst consensus
ConsensusBuy
Consensus score2.33
Analyst opinions3
Strong Sell count0
Sell count0
Hold count1
Buy count2
Strong Buy count0
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Ownership
- Promoter
- 71.42%
- FII
- 2.57%
- MF
- 11.15%
- Other
- 14.86%
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
With EPS Growth And More, Anthem Biosciences (NSE:ANTHEM) Makes An Interesting Case simplywall.st
Anthem Biosciences - Jio Financial Services among 6 stocks showing bullish RSI upswing The Economic Times
Anthem Biosciences to host Q1 FY27 earnings call on July 22 scanx.trade
Anthem Biosciences confirms no encumbrance on promoter shares in FY26 scanx.trade
Anthem Biosciences IPO opens for subscription: Check price band, lot size and key points to know Upstox
Anthem Biosciences IPO: Issue booked nearly 64x on day 3, QIBs take lead; here's how to check allotment Upstox
Events
- annual General MeetingAGM
- board MeetingsQuarterly Results
- dividendRs.2.0000 per share(100%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingPOM
- board MeetingsQuarterly Results
Discussion and sentiment for Anthem BioSciences
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Community discussion loads as you approach this section.
Business information
What the company does
Anthem Biosciences Limited is an India-based contract research, development and manufacturing organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing. The Company’s segments include CRDMO and Speciality Ingredients. The Company helps new and established biotech’s and big pharma, develop, optimize and test proteins, monoclonal antibodies, peptides, large molecules, small molecules, toxins and others. In addition to product research and development, it helps test drugs for safety, efficacy (in vitro and in vivo), pre-clinical animal studies in a GLP facility, clone development, antibody drug conjugates, research and development and manufacture of highly potent compounds, flow chemistry-based production and large-scale commercial product manufacture. Its CRDMO Services include Large Molecules, Small Molecules, HPAPI, Peptides, Lipids, ADCs and Oligonucleotides.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- ANTHEM
- BSE Code
- 544449
Stock FAQ
What is the symbol and ISIN of Anthem BioSciences?
Anthem BioSciences has the symbol ANTHEM and ISIN - INE0CZ201020.
What is the latest recorded price of Anthem BioSciences?
The latest available recorded price of Anthem BioSciences is INR 822.20 as of 2026-08-06T20:48:52.564Z. This is a source-stamped snapshot, not a live quote.
What are the year high and year low of Anthem BioSciences?
Year high: INR 873.25. Year low: INR 579.45.
What is the market capitalization of Anthem BioSciences?
Market capitalization: INR 46,624.99 crore.
What is the P/E ratio of Anthem BioSciences?
P/E ratio: 75.18.
What is the dividend yield of Anthem BioSciences?
Dividend yield: 0.24%.
How is the financial performance of Anthem BioSciences based on revenue, net income, and EPS?
Revenue: INR 2,124.33 crore. Net income: INR 591.79 crore. EPS: INR 10.48.
What are the price-to-book and price-to-sales ratios of Anthem BioSciences?
Price-to-book ratio is unavailable in the current source. Price-to-sales ratio: 21.95.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.